- Accueil >
- Publications >
- Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial
Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial
Auteurs
Luc Cabel, Frédérique Berger, Paul Cottu, Delphine Loirat, Aurore Rampanou, Etienne Brain, Stacy Cyrille, Hugues Bourgeois, Nicolas Kiavue, Elise Deluche, Sylvain Ladoire, Mario Campone, Jean-Yves Pierga, Francois-Clement Bidard
Résumé
Abstract
Background
CirCe01 trial aimed to assess the clinical utility of circulating tumour cell (CTC)-based monitoring in metastatic breast cancer (MBC) patients beyond the third line of chemotherapy (LC).
Methods
CirCe01 was a prospective, multicentre, randomised trial (NCT01349842) that included patients with MBC after two systemic LC. Patients with ≥5 CTC/7.5 mL (CellSearch®) were randomised between the CTC-driven and the standard arm. In the CTC arm, changes in CTC count were assessed at the first cycle of each LC; patients in whom CTC levels predicted early tumour progression had to switch to a subsequent LC.
Results
Greater than or equal to 5 CTC/7.5 mL were observed in
Conclusions
Due to the limited accrual and compliance, this trial failed to demonstrate the clinical utility of CTC monitoring.
Clinical Trial Registration
NCT, NCT01349842,